Related Experiment Video

Updated: Apr 19, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K

Metallothionein 2A genetic polymorphism and its correlation to coronary heart disease

X-Y Yang1, J-H Sun, H-Y Ke

  • 1Department of Cardiology; Integrated Laboratory, No.1 People's Hospital, No.3 Hospital Affiliated to Soochow University, Changzhou, Jiangsu Province, China. shineroar@163.com.

European Review for Medical and Pharmacological Sciences
|January 4, 2015
PubMed

Insights

The metallothionein 2A (MT2A)-838G/C gene polymorphism is linked to coronary heart disease (CHD) in China. The MT2A-838C allele increases CHD risk and disease severity, suggesting it is a susceptibility gene.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Molecular Biology

Background:

  • Metallothionein 2A (MT2A) plays a role in cellular protection.
  • Gene polymorphisms can influence susceptibility to complex diseases like coronary heart disease (CHD).

Purpose of the Study:

  • To investigate the association between the MT2A gene-838G/C polymorphism and CHD in the Han population of Jiangsu, China.
  • To determine if this polymorphism impacts the severity of coronary artery disease.

Main Methods:

  • Genotyping of the MT2A-838G/C polymorphism using mono-labeled fluorescent probes in 287 CHD patients and 226 controls.
  • Analysis of clinical variables including blood lipids, glucose, BMI, and coronary artery disease extent using Gensini's score.

Main Results:

  • Significant differences in MT2A-838G/C genotype and allele frequencies were observed between CHD patients and controls.
  • The MT2A-838C allele was more frequent in CHD patients (31.4%) than controls (24.6%).
  • Carrying the C allele (GC+CC genotypes) increased CHD risk (OR=1.562) and was an independent risk factor, associated with higher Gensini scores.

Conclusions:

  • The MT2A-838G/C gene polymorphism is significantly correlated with coronary heart disease.
  • The MT2A-838C allele may act as a CHD-susceptible gene.
  • This polymorphism appears to influence the extent of coronary artery disease.
Abstract

More Related Videos

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.2K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
162.8K
Translation01:31

Translation

Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
23.4K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
82
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
198